SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Themis Medicare enters into Supply & Distribution Agreement with Novartis India

17 Sep 2013 Evaluate

Themis Medicare (Themis) has entered into a Supply & Distribution Agreement with Novartis India (Novartis) on August 16, 2013. As per agreement, Themis has agreed to manufacture and supply and Novartis has agreed long term exclusive purchase from Themis Diclofenac Sodium 75 mg per ml Injection as finished dosage pharmaceutical form on certain commercial terms and conditions for Indian market.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Themis Medicare Share Price

90.25 4.97 (5.83%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×